Enterprise name	RĪGAS FARMACEITISKĀ FABRIKA AS				
Registration No	0 0 0 3 0 0 0 7 6				
-					
Registration No of tax-payer	4 0 0 0 3 0 0 7 6 5				
Address <u>Rīga , Duntes</u>	16/22				
Phone <u>67 355 550 ,</u>	<u>, 67 355 548</u> Fax <u>67 391 790</u>				

The basic kind of activity: *manufacturing of medicines*

Unit: LVL and EUR

STATEMENTS OF FINANCIAL POSITION

for the period ended 31 December 2010

DATA OF THE ENTERPRISE

1 Full name of the enterprise :	a/s " Rīgas Farmaceitiskā Fabrika "
2 The legal status of a society:	Joint-stock company
3 The state registration in the register of the enterprises	: 000300076 Riga, 26.03.1991.
4 The state registration in the commercial register :	40003000765 Riga, 28.06.2004.
5 VAT number of the registration :	LV 40003000765
6 The legal address and phones of the enterprise :	Riga, Duntes str. 16/22 , Latvija, LV-1005
	Phones: 67 355 550 Fax: 67 391 790 67 355 551 67 355 548
7 The basic kind of activity:	manufacture of medicines
8 The accounting period :	2010 year 01 january – 31 december
9 The enterprises head :	Kaspars Bāliņs p/k 190571-12768 Post: chairman of board
10 Data on the basic shareholders (participants) : Share of actions	Bergere Irina p/k 091152-12750 (shares) (%) 36,48 %
Share of actions	Livšica Helena p/k 111148-10719 (shares) (%) 32,86 %
Share of actions	Oskerko Jānis p/k 230647-11840 (shares) (%) 9,09 %
11 Bank requisites :	NORDEA BANKA SWIFT: NDEA LV 2X
	account Nr. LV 32 NDEA OOOOO 80 121 297 (LVL)
	LV 26 NDEA OOOOO 8O 146 528 (LVL)
	SWEDBANK SWIFT: HABA LV 22
	account Nr. LV 51 HABA O551 OO415 6810 (multiple currency)
12 The chief accountant :	Natalja Gorbunova p/k 270860-10402
13 Average number of workers :	62
14 Structure of the enterprise	
(the name of subdivisions, the addreses):	Administrāsija laboratorija
	<i>Administrācija</i> , <i>laboratorija</i> Address: Rīga, Duntes iela 16/22, Latvija, LV-1005
	Noliktavas telpas Address : Rīga, Duntes iela 16/22 , Latvija, LV-1005 Rīga, Maza Ozola 6 , Latvija, LV-1005
	Galēniskais iecirknis Address: Rīga, Duntes iela 16/22, Latvija, LV-1005
	Fasēšanas iecirknis

Address : Rīga, Maza Ozola 6 , Latvija, LV-1005

Ārstniecisko drogu iecirknis

Address: Rīga, Duntes iela 16/22, Latvija, LV-1005

a/s "Rīgas Farmaceitiskā Fabrika"

reg. No 40003000765 Rīga , Duntes iela 16/22

BALANCE SHEET

for the period ended 31 december 2010

Period

01.01.2010.

			Period		01.01.2010.	
	(I P o	urrono	v EUD roto	= 0.702804	31.12.2010.	
ASSETS	LBC	Line code	The end of reporting period 2010.g. 01.01 31.12. LVL	The end of reporting period 2010.g. 01.0131.12. EUR	The end of reporting period 2009.g. 01.01 31.12. LVL	The end of reporting period 2009.g. 01.0131.12
1. Long - term investments						
I Intangible investments						
1 Research and development costs		10				
2 Concessions, patents, licenses, trade-marks and similar rights		20	39 934	56 821	50 883	72 40
3 Other intangible rights		21				
4 Intangible value of enterprise		30		-		-
5 Advance payments of intangible investments		40	140,00	199		
TOTALLY	1		40074	57020	50883	7240
II Fixed assets						
1 Lands, buildings, constructions and prennial plantations		60	411 806	585 947	457 701	651 25
2 Long-term leased fixed		70				
3 Technological equipment and machines	_	80	142 744	203 106	174 865	248 81
4 Other fixed assets and inventory	+	90	43 419	61 780	58 679	83 49
5 Forming of fixed assets and costs of unfinished objects of constructio	_	100			-	
6 Advance payments for fixed assets TOTALLY	2	110	597969	850833	691245	9835
III Long - term financial investments	+		397909	650655	091245	9033
1 Participation in capital of related companies	_	130				
Loans to related companies	_	140				
3 Participation in capital of affiliated companies		150				
4 Loans to affiliated companies	_	160				
5 Other securities and investments		170				
6 Other loans	1	180				
7 Own stocks and shares		190				
8 Loans to joint owners and administration		200				
TOTALLY			0	0	0	
1. TOTALLY			638043	907853	742128	10559
2. Current assets						
I Stocks		•••		246.702	261.20	
1 Row materials, direct materials and auxiliary materials	3	230	222 495	316 582	261 287	371 7
2 Unfinished products	4	240	10 416	14 821	12 864	18 30
3 Complete products and goods for sale	5	250 260	147 335	209 639	112 495	160 00
4 Unfinished orders 5 Advance payments for goods	6	270	6 815	9 697	48 507	69 0
6 Work animals and productive animals	7	280	150	213	150	2
TOTALLY	+ ′	200	387211	550952	435303	6193
II Debtors			507211	330732	103000	0170
1 Customers and client debts	8	300	102 071	145 234	199 707	284 15
2 Related companies debts		310	-		-	
3 Affiliated companies debts		320	-		_	
4 Other debts	9	330	89 538	127 401	197 448	280 94
5 Undeposited shares in business capital		340				
6 Short - term loans to joint owners and administration	9	350	1	1	205	29
7 Accrued income	10	360	1 889	2 688	5 914	8 41
TOTALLY			193499	275324	403274	5738
III Securities and participation in capitals		380				
1 Participation in capital of related companies			1			
Participation in capital of related companies Own stocks and shares		390			_	
Participation in capital of related companies Own stocks and shares Other securities and participation in capitals		400				
Participation in capital of related companies Own stocks and shares Other securities and participation in capitals TOTALLY			0	0	0	
Participation in capital of related companies Own stocks and shares Other securities and participation in capitals TOTALLY IV Cash assets (TOTAL)	11	400		·		16.63
Participation in capital of related companies Own stocks and shares Other securities and participation in capitals TOTALLY	11		3 477 584187	0 4 947 831223	11 682 850259	16 62 120981

LIABILITIES		Line code	The end of reporting period 2010.g. 01.01 31.12. LVL	The end of reporting period 2010.g. 01.0131.12. EUR	The end of reporting period 2009.g. 01.01 31.12. LVL	The end of reporting period 2009.g. 01.0131.12. EUR
1. Equity capital						
Equity capital						
1 Stock or share capital (equity capital)	12	450	663 000	943 364	663 000	943 364
2 Stock issue extra charge		460	-		-	
3 Long - term investment re-estimation reserve		470	-		-	
4 Prescribed reserves		480	-		-	
5 Reserves for own stocks and shares		490	-		-	
6 Reserves prescribed by enterprise		500	-		-	20.026
7 Other reserves		510	(216.404)	(200.020)	28 060	39 926
8 Retained profit of previous years	-	530	(216 484)	(308 029)	739 748	1 052 567
9 Retained profit of the year of accountant TOTALLY		540	149 454	212 654	(984 292) 446516	(1 400 521)
1. TOTALLY			595970 595970	847989 847989	446516	635335 635335
			393970	04/909	440510	055555
2. Stockpiles	-					
Stockpiles 1 Reserves for pensions and similar obligations		560				
2 Reserve for prospective taxes	13	570	28 331	40 311	41 829	59 517
3 Other stockpiles	13	580	20 657	29 392	14 001	19 922
TOTALLY	13	300	48988	69704	55830	79439
2. TOTALLY			48988	69704	55830	79439
3. Creditors			10,00	0,701	0000	1,710,7
I Long - term debts						
1 Funded borrowings		600	_		_	
2 Borrowings for shares		610	_		_	
3 Bank borrowings		620	_		-	
4 Other borrowings		630	-		-	
5 Customers advanced payments		640	-		-	
6 Debts to suppliers and contractors		650	-		-	
7 Bills to be paid		660	-		-	
8 Borrowings from related companies		670	-		-	
9 Borrowings from affiliated companies		680	-		-	
10 Tax and social security payments		690	-		-	
11 Other creditors	14	700	-		-	
12 Deferred income		710	-		-	
13 Dividends of the year of account		720	-		-	
14 Unpaid dividends of previous years		730	-		-	
TOTALLY II Short - term debts			0	0	0	0
		750				
1 Funded borrowings 2 Borrowings for shares	_	750 760	-		-	
3 Bank borrowings		770				
4 Other borrowings		780	-		<u> </u>	
5 Customers advanced payments		790	_	_	465 000	661 635
6 Debts to suppliers and contractors	14	800	155 938	221 880	597 073	849 558
7 Bills to be paid		810	-		-	
8 Borrowings from related companies		820				
9 Borrowings from affiliated companies		830	-		-	
10 Tax and social security payments	14	840	15 076	21 451	14 513	20 650
11 Other creditors	14	850	8 636	12 288	13 455	19 145
12 Deferred income		860	-		-	
13 Dividends of the year of account		870	-		-	
14 Accrued liabilities		880	397 622	565 765	-	
TOTALLY			577272	821384	1090041	1550989
3. TOTALLY			577272		1090041	1550989
BALANCE			1222230	1739077	1592387	2265763

a/s "Rīgas Farmaceitiskā Fabrika"

reg. No 40003000765 Rīga , Duntes iela 16/22

STATEMENTS OF COMPREHENSIVE INCOME

for the period ended 31 december 2010

Period 01.01.2010.

31.12.2010.

(LB currency EUR rate = 0.702804)

2. Cost of sales (prime cost) 16 20 -1226533 -1745199 -1349109 -1919609 3. Gross profit or loss 30 669663 952845 432911 615977 4. Sales Distribution costs: 16 40 -240454 -342135 -317451 -451692 5. Administration costs 16 50 -275895 -392563 -282156 -401472 6. Other operating income 17 60 4115 5855 1310 1864 7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80 80 80 9. Income from securities and long - term loans 90 90 90 90 90 10. Other interests receivable and similar income 100 110 90 <th></th> <th></th> <th>(-</th> <th>D Cuii</th> <th>ency Lort rate</th> <th>= 0.70200+)</th> <th></th> <th></th>			(-	D Cuii	ency Lort rate	= 0.70200 +)		
2. Cost of sales (prime cost) 16 20 -1226533 -1745199 -1349109 -1919609 3. Gross profit or loss 30 669663 952845 432911 615977 4. Sales Distribution costs: 16 40 -240454 -342135 -317451 -451692 5. Administration costs 16 50 -275895 -392563 -282156 -401472 6. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80 80 80 9. Income from securities and long - term loans 90 90 90 90 10. Other interests receivable and similar income 100 110 110 110 11. Amounts written off investments 110 120 120 120 13. Profit or loss before extraordinary items and tax 19 130 139514 198511 -975305 -1387734 14. Extraordinary charges 150	No	Special rate	Note	ROW	reporting period 2010.g. 01.01 31.12.	reporting period 2010.g. 01.01 31.12.	reporting period 2009.g. 01.01 31.12.	reporting period 2009.g. 01.01 31.12.
3. Gross profit or loss	1.	Net turnover	15	10	1896196	2698044	1782020	2535586
4. Sales Distribution costs: 16 40 -240454 -342135 -317451 -451692 5. Administration costs 16 50 -275895 -392563 -282156 -401472 6. Other operating income 17 60 4115 5855 1310 1864 7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80	2.	Cost of sales (prime cost)	16	20	-1226533	-1745199	-1349109	-1919609
5. Administration costs 16 50 -275895 -392563 -282156 -401472 6. Other operating income 17 60 4115 5855 1310 1864 7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80 80 80 9. Income from securities and long - term loans 90 90 90 90 10. Other interests receivable and similar income 100 90 90 90 11. Amounts written off investments 110 90 90 90 90 12. Interest payable and similar changes 120 90<	3.	Gross profit or loss		30	669663	952845	432911	615977
6. Other operating income 17 60 4115 5855 1310 1864 7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80 80 80 9. Income from securities and long - term loans 90 90 90 10. Other interests receivable and similar income 100 90 90 11. Amounts written off investments 110 90 90 90 12. Interest payable and similar changes 120 90<	4.	Sales Distribution costs:	16	40	-240454	-342135	-317451	-451692
7. Other operating expenses 18 70 -17915 -25491 -809919 -1152411 8. Income from participation in capital of related and affiliated companies 80 80 80 9. Income from securities and long - term loans 90 90 90 90 10. Other interests receivable and similar income 100	5.	Administration costs	16	50	-275895	-392563	-282156	-401472
10	6.	Other operating income	17	60	4115	5855	1310	1864
Income from securities and long - term loans 90	7.	Other operating expenses	18	70	-17915	-25491	-809919	-1152411
10. Other interests receivable and similar income 100 11. Amounts written off investments 110 12. Interest payable and similar changes 120 13. Profit or loss before extraordinary items and tax 19 130 139514 198511 -975305 -1387734 14. Extraordinary income 140 15. Extraordinary charges 150 16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	8.			80				
11. Amounts written off investments 110 12. Interest payable and similar changes 120 13. Profit or loss before extraordinary items and tax 19 130 139514 198511 -975305 -1387734 14. Extraordinary income 140 15. Extraordinary charges 150 16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	9.	Income from securities and long - term loans		90				
12. Interest payable and similar changes 120 13. Profit or loss before extraordinary items and tax 19 130 139514 198511 -975305 -1387734 14. Extraordinary income 140 -975305 -1387734 15. Extraordinary charges 150 -975305 -1387734 16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	10.	Other interests receivable and similar income		100				
13. Profit or loss before extraordinary items and tax 19 130 139514 198511 -975305 -1387734 14. Extraordinary income 140 150	11.	Amounts written off investments		110				
14. Extraordinary income 140 15. Extraordinary charges 150 16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	12.	Interest payable and similar changes		120				
15. Extraordinary charges 150 16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	13.	Profit or loss before extraordinary items and tax	19	130	139514	198511	-975305	-1387734
16. Profit or loss before tax 19 160 139514 198511 -975305 -1387734 17. Tax on profit or loss for the financial period 20 170 0 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	14.	Extraordinary income		140				
17. Tax on profit or loss for the financial period 20 170 0 0 0 0 18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	15.	Extraordinary charges		150				
18 Tax on profit (pustpone) or loss for the financial period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	16.	Profit or loss before tax	19	160	139514	198511	-975305	-1387734
18 period 21 170 13498 19206 -5726 -8147 19 Other taxes 22 180 -3558 -5063 -3261 -4640 20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	17.	Tax on profit or loss for the financial period	20	170	0	0	0	0
20 Profit or loss for the financial period 23 190 149454 212654 -984292 -1400521	18		21	170	13498	19206	-5726	-8147
	19	Other taxes	22	180	-3558	-5063	-3261	-4640
FPS k-t 0 2254 0 3207 -1 4846 -2 1124	20	Profit or loss for the financial period	23	190	149454	212654	-984292	-1400521
		FP\$ k_t			N 225 <i>4</i>	ი ვეიუ	-1 4846	-2 1124

Enterprise name

RĪGAS FARMACEITISKĀ FABRIKA A/S

0 0 0 3 0 0 0 7 6 Registration No

Registration No of tax-payer 4 0 0 0 3 0 0 7 6 5

Address Rīga , Duntes iela 16/22

Phone **67 355 550, 67 355 548** Fax 67 391 790

Unit: LVL and EUR

OVERWIEW OF EQUITY CAPITAL CHANGES

Period 01.01.2010.

		(LB curren	cy EUR rate =	0.702804)	31.12.2010.
	for the period ended 31 december 2010	The end of	The end of	The end of	The end of
		reporting period	reporting period	reporting period	reporting period
		2010.g. 01.01	2010.g. 01.01	2009.g. 01.01	2009.g. 01.01
		31.12. , LVL	31.12. , EUR	31.12. , LVL	31.12. , EUR
1.	Share capital	31.12. , EVE	51.12. , LOIX	31.12. , EVE	31.12. , LOIX
''	Post-balance residue on: 01.01.2010.	663 000	943 364	663 000	943 364
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	663 000	943 364	663 000	943 364
2.	Share premium				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	0	0	0	0
3.	Revaluation reserve of long-term investments				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	0	0	0	0
4.	Mandatory reserves				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	0	0	0	0
5.	Revaluation of own stocks of shares reserves				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	0	0	0	0
6.	Reserves determined by company statute				
	Post-balance residue on: 01.01.2010.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2010.	0	0	0	0
7.	Other reserves				
	Post-balance residue on: 01.01.2010.	28 060	39 926	28 060	39 926
	Increase :	0	0	0	0
	Decrease :	28060	39 926	0	•
	Post-balance residue on: 31.12.2010.	0	0	28 060	39 926
8.	Retained profit				
	Post-balance residue on: 01.01.2010.	-216 484	-308 029	739 748	1 052 567
	Post-balance residue on: 31.12.2010.	-67 030	-95 375	-984 292	-1 400 521
9.	Equity capital (total)				
	Post-balance residue on: 01.01.2010.	474 576	675 261	1 430 808	2 035 856
L	Post-balance residue on: 31.12.2010.	595 970	847 989	446 516	635 335

a/s "Rīgas Farmaceitiskā Fabrika "

reg. No 40003000765 Rīga , Duntes iela 16/22

STATEMENT OF CASH FLOW

for the period ended 31 december 2010

Period 01.01.2010. (LB currency EUR rate = 0.702804) 31.12.2010. The end of The end of The end of The end of Note No reporting period reporting period reporting period reporting period 2010.g. 2010.g. 2009.g. 2009.g. 01.01.-31.12., 01.01.-31.12. 01.01.-31.12. 01.01.-31.12., LVL **EUR** LVL **EUR CASH FLOW from operating activities** Net profit (before enterprise income tax) 139514 198511 -975305 -1387734 Corrections to adjust the profit of revision year to hard cash of economic activities : Depreciation of fixed assets and intangible investments 141325 201087 148128 210767 Profit or loss from sale of fixed assets and intangible investments 18522 0 13017 Expenditures per cent 0 0 Provisions fornon-used holidays 6657 9472 -10276 -14621 Other reserves 0 0 0 Debt expenditures of doubtful debtors 0 0 0 0 Incoming of next periods 0 0 0 0 The taxes to deduct from net profit (property tax) -3558 -5063 -3261 -4640 Paid enterprise income tax The changes of the current assets and liabilities: 248994 Provisions 48092 68429 354287 Debts of customers and subscribers 97636 138924 1480 2106 Expenditures of next periods 4025 5727 875 1245 Others debtors 108113 153831 323144 459792 Advance payments from customers -465000 -661635 465000 661635 Debts to suppliers and contractors -43514 -61915 -155580 221370 Other creditors -6056 13873 -4256 9750 Net cash provided by (used in) operating activities 29034 41312 65966 93861 **CASH FLOW from investing activities** Fixed assets purchase costs -37239 -52986 -61476 -87472 Investment costs 0 0 Fixed assets selling income 0 6389 9091 0 Investment selling income 0 0 0 Company equity 0 0 0 0 Dividends received 0 0 0 Net cash provided by (used in) investing activities -37239 -52986 -78382 -55087 **CASH FLOW from financing activities** Income from issue 0 0 0 0 Loans from credit institutions 0 0 0 0 Loans to creditirs 0 0 0 0 Payments for leasing liabilities 0 0 0 0 Other loans 0 0 0 0 Fixed assets investments 0 0 0 0 Cost of dividends 0 0 0 0 Net cash provided by (used in) financing activities 0 0 0 0 Net increase (decrease) in cash -11675 10879 -8205 15479 Cash at the beginning of the year 11682 16622 803 1143 Cash at the end of the year 3477 4947 11682 16622

A/S " RĪGAS FARMACEITISKĀ FABRIKA "

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 December 2010

ACCOUNTING POLICES

(1) Basis of preparation

The financial statements have been prepared in accordance with general accounting principles that correspond to the laws of the Republic of Latvia.

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (the EU).

All amounts presented in these financial statements are denominated in EUR of the Bank of Latvia LVL rate of exchange as at date of report (0,702804).

The financial statements reporting period is from 01 January 2010 till 31 December 2010. The company's accounting polices have not changed in comparison with the previous year. The financial statements reporting period is verified by auditor.

1. INTANGIBLE ASSETS

	s on research activities LVL / EUR	Licenses and patents LVL / EUR	Company's intangible value LVL / EUR	Total LVL / EUR
Historical cost as of 1 January 2010	0	94 153 / 133 966	3 682 / 5 239	97 834 / 139 205
Additions	0	4 742 / 6 747	0	4 742 / 6 747
Disposals	0	3 400 / 4 838	0	3 400 / 4 838
Historical cost as of 31 December 2010	0	95 495 / 135875	3 682 / 5 239	99 177/ 141 114
Accumulated depreciation before 2010	0	43 269 / 61 566	3 682 / 5 239	46 951 / 66 805
Excluded on disposal	0	0	0	0
Accumulated depreciation in 2010	0	12 151 / 17 289	0	12 151 / 17 289
Net book value as of 31 December 2010	0	40 074 / 57 020	0	40 074 / 57 020

2. FIXED ASSETS

	Land LVL / EUR	Buildings LVL / EUR	Equipmen t LVL / EUR	Vehicles LVL / EUR	Other fixed assets LVL / EUR	Pendin g objects LVL / EUR	Total LVL / EUR
Historical cost as of 1	67 473 /	581 600 /	501 696 /	74 567 /	175 506 /	0	1 400 842 /
January 2010	96 005	827 542	713 849	106 099	249 723		1 993 218
Additions	0	0	28 775 /	0	7 122 /	0	35 897 /
			40 943		10 134		51 077
Disposals	0	0	(1 376)/	0	(2 208) /	0	(3 584) /
			(1 958)		(3 142)		(5 100)
Historical cost as of	67 473 /	581 600 /	529 095 /	74 567 /	180 420 /	0	1 433 155 /
31 December 2010	96 005	827 542	752 834	106 099	256 715		2 036 195
Accumulated	0	191 372 /	326 830/	47 221 /	144 173 /	0	709 596 /
depreciation before		272 298	465 037	674 189	205 140		1 009 664
2010							
Accumulated	0	45 895 /	60 897 /	9 012 /	13 370 /	0	129 174 /
depreciation in 2010		65 303	86 649	12 823	19 024		183 799
Excluded on disposal	0	0	(1 376)/	0	(2 208) /	0	(3 584) /
			(1 958)		(3 142)		(5 100)

Net book value as of	67 473 /	344 333 /	142 744 /	18 334 /	25 085 /	0	597 969 /
31 December 2010	96 005	489 942	203 106	26 087	35 693		850 833

3, 4. RAW AND AUXILIARY MATERIALS

Raw and auxiliary materials are presented in financial statement at their purchasing price.

5. GOODS FOR SALE

Goods for sale are presented in financial statement at their net realizable value

6. ADVANCE PAYMENTS

Advance payments include advance payments for following period expenses connected with real estate, raw and ancillary materials as well as advance payments for fixed assets.

7. Work animals – guard dog.

8. ACCOUNTS RECEIVABLE

All accounts receivable are short-term.

9. OTHER DEBTORS

As of 31 As of 01
December January 2010
2010 LVL / EUR
LVL / EUR

1889/2688

5 9 1 4 / 8 4 1 5

Corporate income tax overpayment	44 971 / 63 988	44 971 / 63 988
VAT overpayment	44 567 / 63 413	152 477/216955
Other income overpayment	0/0	0/0
Short-term loans to partners and employees	1/1	205 / 292
Total	89 539 / 127 402	197 653/281235

Last year VAT overpayment will be used to cover VAT taxes in 2011.

10. DEFERRED EXPENSES

	As of 31 December 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Press subscription	493 / 701	479 / 682
Insurance	829 / 1 180	1 875 / 2 668
Other	567 / 807	3 560 / 5 065

11 CASH

Total

П. САЗП	As of 31 December 2010 LVL / EUR	As of 01 January 2010 LVL / EUR
Cash on hand	431 / 613	847 / 1 205
Current account with NORDEA BANKA (LVL)	2 694 / 3 833	8 857 / 12 602
Current account with SWEDBANKA (LVL)	352 / 501	1 978 / 2 815
Current account with SWEDBANKA (currency)	0	0
Total	3 477 / 4 947	11 682 / 16 622

The share capital of the Company consisted of 663,000 LVL; that is 660,000 common voting shares and 3,000 common nonvoting shares with nominal value 1 LVL per share.

13. PROVISIONS

Provisions for the reporting year consisted of vacation salaries and other remaining balance amounts.

14. CREDITORS

	As of 31 December	As of 01 January
	2010	2010
	LVL / EUR	LVL / EUR
Customer s advanced payments	0/0	465 000 / 661 635
Debtor overpayment	394 245 / 560 960	263 793 / 375 344
Due to suppliers	159 315 / 226 685	333 280 / 474 215
Salary for December	8 636 / 12 288	13 455 / 19 145
Taxes and social security payment	15 076 / 21 451	14 513 / 20 650
Corporate income tax	0/0	0/0
Total	577 272 / 821 384	1 090 041 / 1 550 989

15. SALES

LVL / EUR

Total sales	1 896 196 / 2 698 044
including : - operating income	1 782 689 / 2 536 538
- other operating expenses	113 507 / 161 506

16. SALES EXPENSES

Production expenses	1 226 533 / 1 745 199
Sales expenses	240 454 / 342 135
Administrative expenses	275 895 / 392 563
Total expenses	1 742 882 / 2 479 897
Profit or Loss for the year	153 314 / 218 147

17. OTHER OPERATING INCOME

Bank interest for application of funds from current account	0/0
Income from currency fluctuations	996 / 1 417
Other	3 119 / 4 438
Total	4 115 / 5 855

18. OTHER OPERATING EXPENSES

Interest payments (leasing)	0/0
Expenses from currency fluctuations	6 415 / 9 128
Fines paid	16 / 23
Provisions for vacations	0/0
Donations	2/3
Previous periods expenses that are included in current statement	0/0
Other	11 482/ 16 337
Total expenses	17 915 / 25 491

19. PROFIT OR LOSS FOR THE YEAR BEFORE TAX	139 514 / 198 511
--	-------------------

20. CORPORATE INCOME TAX (advance payments)	0/0
21. CORPORATE INCOME TAX /postpone/	(-)13 498 / (-) 19 206
22. OTHER TAXES	3 558 / 5 063
23. NET PROFIT OR LOSS	149 454 / 212 654

24. The average number of employees in 2010 was 62.

A/S "RĪGAS FARMACEITISKĀ FABRIKA" GOVERNING BODY REPORT

JSC "Riga Pharmaceutical Plant" is situated in Riga, 16/22 Duntes street and 6 Maza Ozolu street. The enterprise is the largest producer of finite pharmaceuticals, medical plants and drugs in Latvia. The factory was registered in Latvian Commercial Register of Enterprises in 2004. The Company has the licence for opening (activity) of drug manufacturing enterprise and has successfully passed the GMP certificate.

The main business activity of the enterprise lies in the field of manufacturing medicines, medical goods and food supplements. All kinds of produced medicines are generally being realized in Latvia. Nowadays the enterprise produces 128 products, 53 of them are medicines.

In 2010 enterprise computer system was updated. Also syrup and oil packing lines in the packing area were modernised.

In the accounting period enterprise has expanded it's range of goods with 9 new products.

The year 2010 can be viewed as succesful - the enterprise has made 2 698 044 EUR (1 896 196 LVL) turnover, which is 162 458 EUR (114 176 LVL) more than in 2009. The enterprise income in 2010 was 212 654 EUR (149 454 LVL).

The government of the enterprise took the decision to direct the accounting year income to enterprise modernisation. It also hopes that this year gained experience and investments will bring good results for the company in future.

The government of JSC "Riga Pharmaceutical Plant" (later in the text - Enterprise) is responsible for the preparing of intermediate finance report and it's responsible for making financial calculations according to existing standard acts and represent in a true and distinct way the state of company's assets and liabilities, financial performance, profits and loss, as well as that the government statement provides faithful information.

The government of the enterprise is responsible for using a corresponding register system, for preservation of assets of the enterprise and for investigation and elimination of the deceptions and delusions committed by the enterprise. The government of the enterprise is also responsible for the observance of Latvian legislation.